PERSPECTA

News from every angle

← Back to headlines

Morgan Stanley Doubles Price Target for CRISPR Therapeutics

Morgan Stanley has nearly doubled its price target for CRISPR Therapeutics, prompting questions on whether the gene-editing stock is a compelling buy.

30 Jul, 21:58 — 30 Jul, 21:58
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual15d ago

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Read full article →

Related Stories

Luigi Mangione Pleads Guilty to Killing UnitedHealthcare CEO

1h ago

Anthropic's Q2 Revenue Exceeds $11.5 Billion, IPO Valuation Targets $200 Billion by 2028

1h ago

Bezos-Backed Consortium Acquires Minority Stake in Liverpool FC

1h ago

Secondhand Booksellers Suspect AI Firms Behind Bulk Orders

1h ago